ImmunityBio

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May 10, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2023. SO WHAT: If you purchased ImmunityBio securities during the Class Perio.

EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – IBRX

LOS ANGELES, CA / ACCESSWIRE / July 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 23, 2022 and May 10, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 29, 2023.

INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired ImmunityBio securities between May 23, 2022 and May 10, 2023, both dates inclusive (the “Class Period”). Inve.

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $IBRX #Anktiva--ImmunityBio, Inc. (IBRX) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against ImmunityBio, Inc. (IBRX)

The FDA rejected the Anktiva marketing application last month. Since the troubles lie with an outside organization, the company has no control over the resolution. The drug is good, so resubmission, approval, and partnership are all still in play.

ImmunityBio Can Recover From BLA Dip

Carvana

DraftKings

Luckin Coffee

Novavax

Upstart Holdings

vTv Therapeutics

There are some similarities between gambling and buying high-risk, high-reward stocks. In both scenarios, you could make a great deal of money or you could lose all of it.

7 High-Risk, High-Reward Stocks to Buy in June

Diversified Healthcare Trust

Globalstar

Lexicon Pharmaceuticals

Penny stocks are often characterized by their high volatility. Their low price means that even small price changes can equate to significant percentage gains or losses.

4 Penny Stocks To Buy In June According To Insiders

LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023, at 10:00 am Eastern Time (ET) at the Marriott Marquis, New York. An audio webcast of the presentation will be accessible under the “Events & Presentations.

ImmunityBio to Participate in the Jefferies Global Healthcare Conference

NEW YORK , May 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

Being an extremely volatile stock, ImmunityBio, Inc. is not for all investors. Nevertheless, there are tremendous opportunities in ImmunityBio stock for investors who can stomach higher risks and substantial volatility.

ImmunityBio: Amidst Difficulty Is Your Opportunity

LOS ANGELES, CA / ACCESSWIRE / May 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.

FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing

LOS ANGELES--(BUSINESS WIRE)---- $IBRX #IBRX--The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Despite manufacturing deficiencies, the lack of additional FDA requests for preclinical studies or Phase 3 clinical trials hints at eventual approval.

ImmunityBio: Anktiva Rejection Heightens Financial Urgency

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $IBRX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX). Investors who purchased ImmunityBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ibrx. The investigation concerns whether ImmunityBio has violated federal securities laws. On May 11, 2023, Reuters.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ImmunityBio Inc. (IBRX) Investigation

ImmunityBio (NASDAQ: IBRX ) stock is falling on Thursday after the company got a complete response letter from the FDA. That letter has to do with the company's Biologics License Application (BLA) for Anktiva in combination with Bacillus CalmetteGuérin.

Why Is ImmunityBio (IBRX) Stock Down 54% Today?

Perrigo

Immunitybio Inc (NASDAQ:IBRX) stock is crumbling today, down 52.1% at $2.98 at last glance, and earlier as low as $2.45, after the U.S. Food and Drug Administration (FDA) declined to approve its bladder cancer therapy.

2 Pharma Stocks in Focus on FDA Buzz

ImmunityBio Inc shares were sinking fast on Thursday morning after receiving notice from the US Food and Drug Administration that its Biologics License Application was put on hold for its bladder cancer treatment Anktiva. The FDA determined that the BLA cannot be approved in its current form due to deficiencies found during a pre-license inspection of the company's third-party contract manufacturer.

ImmunityBio in dramatic selloff as FDA puts bladder cancer treatment on hold

News for ImmunityBio Stock (IBRX)